Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Yoshida, Go J ^a   Fuchimoto, Yasushi ^b   Osumi, Tomoo ^a   Shimada, Hiroyuki ^a   Hosaka, Seiichi ^a   Morioka, Hideo ^a   Mukai, Makio ^c   Masugi, Yohei ^a   Sakamoto, Michiie ^a   Kuroda, Tatsuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

cancer stem cells (CSCs); CD44 variant isoforms; Li Fraumeni syndrome (LFS)

Indexed keywords

CD44V ANTIGEN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HERMES ANTIGEN; ISOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SUSCEPTIBILITY; CASE REPORT; CHILD; CHRONIC PAIN; FAMILIAL CANCER; FEMALE; GENETIC SCREENING; HEPATOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LOBECTOMY; MISSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; SCHOOL CHILD; TUMOR BIOPSY; BLOOD; GENETICS; LIVER; LIVER TUMOR; MUTATION; PATHOLOGY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHILD; FEMALE; GENES, P53; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; LIVER; LIVER NEOPLASMS; OSTEOSARCOMA; PROTEIN ISOFORMS; TREATMENT OUTCOME;

EID: 84866791348     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-444     Document Type: Article

References (15)

1. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969, 71(4):747-752.
2. Malkin D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238. 10.1126/science.1978757, 1978757.
3. Hisada M, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998, 90(8):606-611. 10.1093/jnci/90.8.606, 9554443.
4. Yamada H, et al. Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer. Int J Cancer 2009, 125(4):973-976. 10.1002/ijc.24432, 19405127.
5. Birch JM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54(5):1298-1304.
6. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21(3):313-320. 10.1002/humu.10185, 12619118.
7. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004, 95(12):930-935. 10.1111/j.1349-7006.2004.tb03179.x, 15596040.
8. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 2003, 20(3):195-201. 10.1023/A:1022931016285, 12741678.
9. Warzecha CC, et al. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 2009, 6(5):546-562. 10.4161/rna.6.5.9606, 2823379, 19829082.
10. Godar S, et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134(1):62-73. 10.1016/j.cell.2008.06.006, 3222460, 18614011.
11. Clarke MF, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344. 10.1158/0008-5472.CAN-06-3126, 16990346.
12. Ishimoto T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19(3):387-400. 10.1016/j.ccr.2011.01.038, 21397861.
13. Prokurat A, et al. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002, 39(5):510-518. 10.1002/mpo.10177, 12228909.
14. Gonzalez KD, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 2009, 46(10):689-693. 10.1136/jmg.2008.058958, 19556618.
15. Kuryu M, et al. Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 1999, 125(11):646-652. 10.1007/s004320050329, 10541973.